Cystectomy ProcedureDescription, Latest Information and Doctors
Cystectomy Overview
Learn About Cystectomy
Cleveland Clinic Main Campus
Christopher Weight is a General Surgeon practicing medicine in Cleveland, Ohio. Dr. Weight is rated as an Elite provider by MediFind in Cystectomy. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Nephrectomy, and Cystectomy. Dr. Weight is currently accepting new patients.
UT MD Anderson Cancer Center
Ashish Kamat is a Urologist practicing medicine in Cary, North Carolina. Dr. Kamat is rated as an Elite provider by MediFind in Cystectomy. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.
University Of Texas Health Science Center San Antonio
Robert Svatek is a Urologist practicing medicine in San Antonio, Texas. Dr. Svatek is rated as an Elite provider by MediFind in Cystectomy. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy. Dr. Svatek is currently accepting new patients.
Summary: This randomized controlled trial evaluates postoperative quality of recovery assessed with the Quality of Recovery-15 questionnaire in adult patients undergoing elective major urological surgery under opioid-free versus opioid-based general anesthesia. Opioid-free anesthesia is a multimodal anesthetic technique that avoids intraoperative opioids by combining non-opioid analgesic and sympatholytic ...
Summary: This is a multicenter, open-label, Phase I/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10566 in patients with high-risk non-muscle-invasive bladder cancer who are ineligible for or refuse radical cystectomy. The study comprises two distinct phases: a dose exploration phase and a proof-of-concept phase.
